Mark has been dedicated to advancing immune-modulatory therapeutic options for patients. Currently, he is developing in vivo B cell protein factories providing durable expression of proteins of therapeutic value, exploiting the ability of B cells to produce immunoglobulin proteins at high levels and to persist for decades. Mark started his industry career at Chiron Vaccines, working with Michael Houghton on exploring the HCV polyprotein for vaccines and subsequently on in vivo DNA delivery platforms to induce cellular immune responses. Thereafter, Mark worked with Dr. Alan Korman at Medarex, advancing fully human immune-modulatory antibodies derived from immunized transgenic mice. Mark is a co-inventor of the anti-PD-1 antibody Nivolumab (Opdivo), the first anti-PD-1 antibody to enter the clinic. Mark is co-inventor of the Nivolumab/Ipilumumab combination as well as the recently approved anti-LAG-3 antibody.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies